CONMED (NYSE:CNMD) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of CONMED (NYSE:CNMD) from a strong-buy rating to a buy rating in a report issued on Saturday morning.

Other equities analysts also recently issued reports about the company. Piper Sandler downgraded CONMED from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $55.00 to $39.00 in a research report on Tuesday, March 17th. Wells Fargo & Company reduced their target price on shares of CONMED from $42.00 to $39.00 and set an “equal weight” rating on the stock in a report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a research note on Thursday, January 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of CONMED in a report on Wednesday, January 21st. Finally, Zacks Research raised shares of CONMED from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $46.20.

CONMED Stock Up 0.2%

Shares of NYSE CNMD opened at $36.72 on Friday. The stock has a market cap of $1.11 billion, a P/E ratio of 20.75, a PEG ratio of 1.61 and a beta of 0.94. The company has a current ratio of 2.14, a quick ratio of 1.01 and a debt-to-equity ratio of 0.81. CONMED has a 12-month low of $33.21 and a 12-month high of $61.08. The business’s fifty day simple moving average is $38.63 and its 200-day simple moving average is $41.12.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, April 29th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The firm had revenue of $317.05 million during the quarter, compared to analysts’ expectations of $310.64 million. CONMED had a return on equity of 13.85% and a net margin of 4.00%.CONMED’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 EPS. As a group, equities analysts predict that CONMED will post 4.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp lifted its position in CONMED by 497.4% in the first quarter. Fifth Third Bancorp now owns 70,623 shares of the company’s stock valued at $2,497,000 after acquiring an additional 58,801 shares during the last quarter. HB Wealth Management LLC grew its holdings in shares of CONMED by 4.0% during the first quarter. HB Wealth Management LLC now owns 16,620 shares of the company’s stock worth $588,000 after purchasing an additional 636 shares during the last quarter. New York State Teachers Retirement System grew its holdings in shares of CONMED by 3.5% during the first quarter. New York State Teachers Retirement System now owns 47,170 shares of the company’s stock worth $1,668,000 after purchasing an additional 1,578 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of CONMED by 14.4% during the first quarter. Janney Montgomery Scott LLC now owns 5,952 shares of the company’s stock worth $210,000 after purchasing an additional 750 shares in the last quarter. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of CONMED during the first quarter worth about $484,000.

Key CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q1 results beat expectations — CONMED reported $0.89 EPS vs. a $0.82 consensus and revenue of $317.1M vs. $310.6M expected; earnings/revenue beats support near-term sentiment and helped calm concerns about recent year-over-year softness. Q1 Earnings Release
• Positive Sentiment: Management raised the organic growth outlook and outlined strategic actions — CONMED now targets 2026 organic growth of roughly 5.0%–6.5%, is exiting the GI business to sharpen focus on higher-growth surgical platforms, and is pursuing debt refinancing to improve the capital structure; those moves aim to lift margins and growth quality over the medium term. Growth Outlook / Strategy
• Positive Sentiment: Analyst takeaways and call materials provide color on execution — sell-side coverage and the earnings call/transcript highlight the company’s plan to refocus and where management expects near-term pressure vs. longer-term upside. Earnings Call Highlights
• Neutral Sentiment: Coverage pieces and deep dives summarize the strategy shift — several outlets (MSN, Zacks, Seeking Alpha) detail the GI exit and segment focus; useful for modeling but not an immediate catalyst by itself. Deep Dive: GI Exit
• Negative Sentiment: Wells Fargo cut its price target to $39 (from $42) and set an “equal weight” rating — the new PT implies only modest upside (~6% at current levels), reducing the near-term analyst-driven upside. Wells Fargo PT Cut
• Negative Sentiment: JPMorgan cut its price target to $40 (from $43) with a “neutral” rating — another downward PT move that keeps analyst expectations conservative despite the earnings beat. JPMorgan PT Cut

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.